Systemic inflammation biomarkers can identify high tumor mutation burden in lung adenocarcinoma.

ABSTRACT:

Background

Tumor mutational burden (TMB) is a recognized biomarker for predicting immunotherapy efficacy in non-small cell lung cancer (NSCLC). Its assessment requires whole-exome sequencing (WES), but the high cost and stringent sample requirements of WES limit its clinical application. This study aims to assess the predictive value of accessible systemic inflammation markers for identifying high TMB lung cancer populations.

Methods

WES was performed on tumor samples and paired peripheral blood from 72 lung adenocarcinoma patients. Genomic analysis identified mutation patterns across different TMB groups. Systemic inflammatory markers, including the neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), lymphocyte-to-monocyte ratio (LMR), and p

SUBMITTER: Fang J 

PROVIDER: S-EPMC12512448 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature